These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21074745)

  • 1. Recombinant factor VIIa in trauma patients without coagulation disorders.
    Scher C; Narine V; Chien D
    Anesthesiol Clin; 2010 Dec; 28(4):681-90. PubMed ID: 21074745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
    Hedner U; Brun NC
    Neuroradiology; 2007 Oct; 49(10):789-93. PubMed ID: 17653706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework.
    Moltzan CJ; Anderson DA; Callum J; Fremes S; Hume H; Mazer CD; Poon MC; Rivard G; Rizoli S; Robinson S
    Transfus Med; 2008 Apr; 18(2):112-20. PubMed ID: 18399845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa. An update on its clinical use.
    Franchini M; Zaffanello M; Veneri D
    Thromb Haemost; 2005 Jun; 93(6):1027-35. PubMed ID: 15968384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
    Selin S; Tejani A
    Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
    Weiskopf RB
    Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of recombinant factor VIIa in hereditary bleeding disorders.
    Poon MC
    Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.
    Mathew P; Young G
    Haemophilia; 2006 Sep; 12(5):457-72. PubMed ID: 16919075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program.
    Arkin S; Cooper HA; Hutter JJ; Miller S; Schmidt ML; Seibel NL; Shapiro A; Warrier I
    Haemostasis; 1998; 28(2):93-8. PubMed ID: 10087434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.
    Carr ME; Martin EJ
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):661-74. PubMed ID: 15350168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of recombinant activated factor VII].
    Reingardiene D; Lazauskas R
    Medicina (Kaunas); 2009; 45(3):248-53. PubMed ID: 19357455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion medicine service policies for recombinant factor VIIa administration.
    Goodnough LT; Lublin DM; Zhang L; Despotis G; Eby C
    Transfusion; 2004 Sep; 44(9):1325-31. PubMed ID: 15318856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
    Weeterings C; Lisman T; de Groot PG
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S12-5. PubMed ID: 18544417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
    Nakar C; Cooper DL; DiMichele D
    Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UK defence medical services guidance for the use of recombinant factor VIIa (rFVIIa) in the deployed military setting.
    Hodgetts TJ; Kirkman E; Mahoney PF; Russell R; Thomas R; Midwinter M
    J R Army Med Corps; 2007 Dec; 153(4):307-9. PubMed ID: 18619169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
    Hong I; Stachnik J
    Am J Health Syst Pharm; 2010 Nov; 67(22):1909-19. PubMed ID: 21048207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
    Levi M; Friederich PW; van der Meer J
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2534-7. PubMed ID: 12532665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa.
    Aitken MG
    Emerg Med Australas; 2004; 16(5-6):446-55. PubMed ID: 15537408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
    Lisman T; Mosnier LO; Lambert T; Mauser-Bunschoten EP; Meijers JC; Nieuwenhuis HK; de Groot PG
    Blood; 2002 Jan; 99(1):175-9. PubMed ID: 11756168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.